首页> 中文期刊> 《美国中华健康卫生杂志》 >泛昔洛韦分别联合干扰素γ、胸腺肽抗乙肝病毒疗效的临床观察

泛昔洛韦分别联合干扰素γ、胸腺肽抗乙肝病毒疗效的临床观察

         

摘要

Objective To observe the efficacy of anti - HBV DNA medicine and different combina-tion. Methods 170 ASC CHB patients were categorized into two groups(group Ⅰ,havs 65 patients,theywere randomised to receive Famcilovir combine with Interferon- γ;group Ⅱ ,havs 105 patients they wererandomised to receive Famcilovir combine with Thymopentin), the controls treat by Interferon - a2b. Re-sult 53.3% of the group Ⅰ and 38.3% of the group Ⅱ had undetectable serum HBV DNA,comparedwith 28.6% in the control group:the people diminition 102 coples/ml,38.8% of whom are in the groupⅠ ,49.5% whom are in the group Ⅱ ,compared with 28.6% in control group(P < 0.025);After treat-ment, they also go down more obviously in HBeAg HbsAg and the group Ⅰ is better than the group Ⅱ.Conclusion Conbination of two different medicine is a useful method, and it may indicate that muchtime is neccssary to receive anti - HBV DNA patients, especially to theose accept immune trcatment.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号